← Eichor
Condition: Melanoma Metastatic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033FMT to Convert Response to Immunotherapy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05251389Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT06771544A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Phase 2 · 1 location(s) · Fudan University · NCT06889610Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Phase 1/Phase 2 · 4 location(s) · Vastra Gotaland Region · NCT03685890T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT06783270A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Phase 2 · 3 location(s) · Abramson Cancer Center at Penn Medicine · NCT03646617Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · University of Miami · NCT06627244In Vivo Liquid Biopsy of Melanoma (Cytophone)
NA · 1 location(s) · Cytoastra · NCT06488365Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07203391Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Phase N/A · 39 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT03605771A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Neoadjuvant Darovasertib in Primary Uveal Melanoma
Phase 3 · 94 location(s) · IDEAYA Biosciences · NCT07015190Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
Phase N/A · 1 location(s) · Medical University of Graz · NCT07635732
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.